智通财经网·2026-01-30 02:37Core Insights - The brain-computer interface (BCI) technology is at a critical industrial turning point, transitioning from academic exploration to commercial application, driven by policy and demand [1][4] - The medical field is the primary battlefield for BCI applications, accounting for 56% of the market, while non-medical sectors such as consumer, industrial, and education represent a combined 44%, indicating strong expansion potential [2][3] Industry Overview - BCI technology enables direct communication between the brain and external devices, facilitating bidirectional interaction from neural signals to control commands. The technology is categorized into invasive, semi-invasive, and non-invasive methods, with no absolute superiority among them; suitability depends on specific applications [1][3] - The global BCI market is projected to grow from $1.98 billion in 2023 to $7.63 billion by 2029, with China's market expected to reach 1.73 billion yuan in 2023, increasing its global share to 12.5% [2] Development Challenges - The BCI industry faces several challenges, including balancing high-throughput, high signal-to-noise ratio signal acquisition with long-term biocompatibility, and the need for breakthroughs in decoding algorithms and adaptive control precision [3] - Clinical challenges include the need for large-scale trials to verify the long-term safety and efficacy of invasive products, as well as the maturity of indication definitions, surgical standardization, and postoperative management systems [3] Global and Domestic Progress - The global BCI industry ecosystem is rapidly developing, with leading companies like Neuralink and Synchron innovating in high-throughput flexible implants and vascular interventions to enhance brain signal acquisition and interaction systems [4] - In China, significant progress has been made in system integration and application implementation, with a diverse enterprise matrix represented by companies such as Strong Brain Technology (non-invasive), Borui Kang (semi-invasive), and Xinwei Medical (interventional) [4] Relevant Companies - Key players in the primary market include Strong Brain Technology, Borui Kang, Ladder Medical, and others; in the secondary market, upstream companies like Maipu Medical and Meihao Medical, midstream companies like Xinwei Medical-B and Xiangyu Medical, and downstream companies like Sanbo Neuroscience are notable [5]